{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00504803",
      "OrgStudyIdInfo": {
        "OrgStudyId": "TJB0601"
      },
      "Organization": {
        "OrgFullName": "University of Liege",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease",
      "OfficialTitle": "Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2011",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2006"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2010",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2010",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "July 19, 2007",
      "StudyFirstSubmitQCDate": "July 19, 2007",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 20, 2007",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "September 1, 2011",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 2, 2011",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yves Beguin",
        "ResponsiblePartyInvestigatorTitle": "Prof",
        "ResponsiblePartyInvestigatorAffiliation": "University of Liege"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Liege",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hematological Malignancies"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "HCT, nonmyeloablative, mesenchymal stem cells, GVHD"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Prevention",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "MSC co-infusion with either HLA-mismatched PBSC or cord blood",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: Mesenchymal stem cell infusion"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "Mesenchymal stem cell infusion",
            "InterventionDescription": "Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Mesenchymal stem cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Day-100 incidence of non-relapse mortality",
            "PrimaryOutcomeTimeFrame": "100 days"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution",
            "SecondaryOutcomeTimeFrame": "365 days"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "V.1. Patients\n\nV.1.1. Diseases\n\nHematological malignancies confirmed histologically and not rapidly progressing:\n\nAML in CR;\nALL in CR;\nCML unresponsive/intolerant to Imatinib but not in blast crisis;\nOther myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis;\nMDS with < 5% blasts;\nMultiple myeloma;\nCLL;\nNon-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);\nHodgkin's disease.\n\nV.1.2. Clinical situations\n\nTheoretical indication for a standard allo-transplant, but not feasible because:\n\nAge > 55 yrs;\nUnacceptable end organ performance;\nPatient's refusal.\nIndication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.\n\nV.1.3. Other inclusion criteria\n\nMale or female; fertile female patients must use a reliable contraception method;\nAge < 75 yrs.\nInformed consent given by patient or his/her guardian if of minor age.\n\nV.1.4. Exclusion criteria\n\nAny condition not fulfilling inclusion criteria;\nHIV positive;\nTerminal organ failure, except for renal failure (dialysis acceptable);\nUncontrolled infection, arrhythmia or hypertension;\nPrevious radiation therapy precluding the use of 2 Gy TBI;\nHLA-identical donor.\n\nV.2. PBSC donors\n\nV.2.1. Inclusion criteria\n\nRelated to the recipient (sibling, parent or child) or unrelated;\nMale or female;\nWeight > 15 Kg (because of leukapheresis);\nFulfills generally accepted criteria for allogeneic PBSC donation;\nInformed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures.\n\nV.2.2. Exclusion criteria\n\nAny condition not fulfilling inclusion criteria;\nHIV positive;\nUnable to undergo leukapheresis because of poor vein access or other reasons.\n\nV.2.3. HLA matching\n\nRelated or unrelated donors who have 1-2 HLA mismatches, as either :\n\nOne antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1\nOne allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1\nTwo allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1\nOne antigenic mismatch + 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.\nOne antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1\n\nV.3. Cord blood unit\n\nBanked cord blood units will be used if they fulfill the following criteria:\n\nNo more than 2/6 HLA mismatches (antigenic mismatch at HLA-A or HLA-B or allelic mismatch at HLA-DRB1)\n> 2.5 x 107 TNC/kg\nStandard validation by FACT/Netcord criteria.",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "All",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Frederic Baron, MD, PhD",
            "OverallOfficialAffiliation": "CHU-ULg",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Yves Beguin, MD, PhD",
            "OverallOfficialAffiliation": "CHU-ULg",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Chantal Lechanteur, PhD",
            "OverallOfficialAffiliation": "CHU-ULg",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Etienne Baudoux, MD",
            "OverallOfficialAffiliation": "CHU-ULg",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Evelyne Willems, MD",
            "OverallOfficialAffiliation": "CHU-ULg",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "CHU Sart Tilman",
            "LocationCity": "Liege",
            "LocationZip": "4000",
            "LocationCountry": "Belgium"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "20109568",
            "ReferenceType": "derived",
            "ReferenceCitation": "Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000019337",
            "ConditionMeshTerm": "Hematologic Neoplasms"
          },
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M20467",
            "ConditionBrowseLeafName": "Hematologic Neoplasms",
            "ConditionBrowseLeafAsFound": "Hematological Malignancies",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}